Extension of convertible debt of SEK 21.7 million

‟Maintained conditions with new maturity 30 June 2017”

During 2011, Bluefish issued the convertible debt serie 2011/2014 with maturity 30 June 2014 of a total amount of SEK 60 million .

At the extraordinary general meeting on 5 July 2013, it was resolved to offer all holders of the convertible debt 2011/2014 the possibility of either extend their holding at maintained conditions but with new maturity 30 June 2017, or to convert to B shares at a price of 5 SEK per share.

The offer to extend the holding with new maturity 30 June 2017 has been accepted by holders of the convertible debt equivalent to an amount of SEK 21.7 million. Another SEK 20 million have been converted to B shares.  The remaining amount of SEK 18.4 million will be repaid at maturity on 30 June 2014.

Full conversion of the convertible debt with maturity 30 June 2017 equivalent to a nominal amount of SEK 21.7 million would increase the company’s share capital by not more than 578 666,60 SEK through the issuance of not more than 2 893 333 B shares.

For more information, contact

Karl Karlsson, President & CEO Bluefish Pharmaceuticals
Tel. 46 8 519 116 00
Email: karl.karlsson@bluefishpharma.com

Susanna Urdmark, CFO Bluefish Pharmaceuticals
Tel. 46 8 519 116 00
Email: susanna.urdmark@bluefishpharma.com

About Bluefish Pharmaceuticals
Bluefish has undergone significant international expansion since the company was founded in 2005. Bluefish focuses on the development, manufacture and sale of generic pharmaceuticals. The company conducts marketing operations in a large number of European markets and is expanding into territories outside Europe. The product portfolio consists of a total of 80 products and is growing.

www.bluefishpharma.com